Key Takeaways:
China Medical System Holdings Ltd. saw its New Drug Application for Comekibart Injection (MG-K10) accepted by China's National Medical Products Administration, a key step toward bringing a new option to the estimated 250 million people in the country with allergic rhinitis.
"The acceptance of the NDA represents an important milestone for the Group’s ophthalmology business, CMS Vision, as it expands its therapeutic focus from ophthalmology into the field of otolaryngology," the company said in a press release.
MG-K10 is a long-acting anti-IL-4Rα antibody that met its primary endpoint in a Phase III trial for moderate-to-severe seasonal allergic rhinitis. Its proposed once-every-four-weeks dosing schedule offers a significant potential advantage over the current standard of care for biologics in its class, which require injections every two weeks.
The regulatory nod opens a path to a substantial market with significant unmet needs. Allergic rhinitis prevalence in China has grown to 17.6%, affecting about 250 million people. According to company filings, 62 percent of patients with moderate-to-severe disease remain inadequately controlled by current treatments like intranasal corticosteroids and antihistamines.
MG-K10 works by blocking the signaling pathways of IL-4 and IL-13, two key cytokines involved in type 2 inflammation. This mechanism is similar to the blockbuster drug Dupixent from Sanofi and Regeneron, but CMS hopes its drug's longer half-life and less frequent dosing will improve patient adherence and reduce the burden of treatment. The company, which holds co-development and exclusive commercialization rights for the drug in China through an agreement with Hunan Mabgeek Biotech, believes MG-K10 has the potential to be the first long-acting anti-IL-4Rα antibody marketed globally.
Current standard therapies for allergic rhinitis have limitations. Long-term use of intranasal corticosteroids can lead to adverse reactions like nosebleeds, while antihistamines are often associated with drowsiness. For the large number of patients whose symptoms are not well-managed by these options, a new biologic like MG-K10 could offer a much-needed alternative by targeting the underlying inflammatory pathway.
The acceptance of the application de-risks the drug's path to market and could lead to a positive revaluation of CMS stock. If final approval is granted, CMS plans to leverage its commercialization network to accelerate the drug's launch, potentially creating a significant new revenue stream and establishing the company as a major player in treating type 2 inflammatory diseases in the region. Investors will now be watching for the NMPA's final decision on the marketing authorization.
This article is for informational purposes only and does not constitute investment advice.
